DEF: EDAP TMS S.A. Schedules 2026 Annual Shareholder Meeting

EDAP TMS S.A. has announced its 2026 Annual Combined General Meeting of Shareholders, set for June 26, 2026, to vote on director elections, financial statements, executive compensation, and strategic capital authorizations.

Summary

• EDAP TMS S.A. is holding its 2026 Annual Combined General Meeting of Shareholders on June 26, 2026, at its registered office in Vaulx-en-Velin, France.
• The meeting agenda includes 32 resolutions, covering the renewal of director terms, approval of financial statements for the fiscal year ended December 31, 2025, advisory votes on executive compensation, and various financial authorizations for the Board of Directors.
• Key proposals include the renewal of directors Ryan Rhodes, Dr. Lance Willsey, Fran Schulz, Josh Levine, and David Horn, and the ratification of David Horn's provisional appointment.
• Shareholders will vote on approving the statutory and consolidated financial statements for the fiscal year ended December 31, 2025, and the allocation of results, which show a net book loss of €3,582,723.
• The meeting will also address delegations of authority to the Board of Directors for capital increases, mergers, spin-offs, and asset contributions, with overall limits on share capital increases set at €2,600,000.
• Resolutions related to executive compensation include an advisory vote to approve compensation and a vote on the frequency of future advisory votes (annual, biennial, or triennial).
• Amendments to the company's bylaws concerning share capital, the Board of Directors, and shareholder meetings are also on the agenda.
• The company is seeking shareholder approval for a delegation of authority to grant free shares to employees and corporate officers, and to increase share capital for employees participating in company savings plans.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as having a negative sentiment due to the significant net losses, declining cash position, and ongoing concerns about the company's ability to continue as a going concern, despite positive commentary on strategic initiatives and future outlook.

Positives

• The company is holding its annual general meeting to ensure shareholder engagement and governance.
• The Board of Directors is seeking to renew the terms of key directors, indicating stability in leadership.
• The company is proposing various financial authorizations to provide the Board with flexibility for future fundraising and strategic initiatives.
• Amendments to bylaws aim to align with French legal and regulatory changes and enhance operational flexibility.
• The company is seeking authorization to grant free shares to employees, a common practice to incentivize and retain talent.

Negatives

• The company reported a net book loss of €3,582,723 for the fiscal year ended December 31, 2025.
• The company's consolidated financial statements show a net loss of €25,883,000 for the fiscal year ended December 31, 2025, and a net loss of €19,018,000 for the fiscal year ended December 31, 2024.
• The company's financial statements indicate a negative equity position, with total equity of €16,523,000 as of December 31, 2025, compared to total liabilities of €50,712,000.
• The company's cash and cash equivalents decreased significantly from €29,836,000 in 2024 to €17,407,000 in 2025.
• The company acknowledges the need to raise significant additional funds beyond the next twelve months to meet cash flow needs until profitability is achieved, and there is uncertainty regarding its ability to continue as a going concern.
• The Board recommends voting against Resolutions 14, 15, and 28, indicating potential shareholder disagreement or strategic misalignment on these specific proposals.

Risks

• The company's ability to continue as a going concern is subject to uncertainty due to ongoing operating losses and the need to raise significant additional funds.
• Failure to raise additional capital on acceptable terms could force the company to restructure operations or delay/terminate product development and commercialization efforts.
• The company relies on single-source suppliers for certain components, which could lead to production delays if supply is interrupted.
• Exchange rate fluctuations, particularly between the euro and the U.S. dollar and Japanese yen, could impact results.
• The company faces intense competition in the markets in which it operates.
• The uncertainty of reimbursement status and levels for procedures performed with its products could affect adoption and revenue.
• Cybersecurity risks and incidents, product liability, and reliance on patents and proprietary technologies are also mentioned as potential risks.

Future Outlook

The company enters 2026 with strong momentum and a clear roadmap for continued growth, focusing on expanding global adoption of Focal One, increasing procedure volumes, advancing new clinical indications, developing increased technology capabilities, and strengthening its commercial infrastructure. The company expects continued expansion in its U.S. and EU business units due to increasing utilization and growing reimbursement support.

Management Comments

• "2025 marked a pivotal year for EDAP, defined by strong execution, accelerating growth, and meaningful progress toward our long-term vision of establishing Focal One Robotic High-Intensity Focused Ultrasound (HIFU) as a global standard of care."
• "The results we achieved reflect both the growing demand for organ-sparing, function preserving treatments and the disciplined execution of our strategic priorities."
• "Patients are becoming more informed and are actively seeking therapies that effectively treat disease while preserving quality of life. HIFU addresses this need directly, offering a non-invasive solution with reduced side effects compared to surgery or radiation."
• "Our strategic focus in 2025 also included refining our business model to prioritize high-growth, high-margin opportunities."
• "Looking ahead, we enter 2026 with strong momentum and a clear roadmap for continued growth."
• "While there is still significant opportunity ahead, we believe we are well positioned to lead the ongoing transformation in the treatment of prostate cancer and beyond."

Industry Context

StockSavvy.ai notes that EDAP TMS S.A.'s focus on HIFU technology aligns with a broader industry trend towards minimally invasive, function-preserving treatments, particularly in urology and oncology. The company's progress in expanding adoption and developing next-generation platforms like Focal One i positions it to capitalize on increasing patient demand for less invasive procedures and growing physician confidence in image-guided focal therapies.

Management Changes

Corporate Governance

Related Party Transactions

• On August 19, 2019, EDAP Technomed Co. Ltd. (Japan) contracted a loan for 80,000,000 JPY, requiring a personal guarantee from its representative director, Mr. Jean-Franois Bachelard. EDAP TMS S.A. counter-guaranteed this loan and agreed to indemnify Mr. Bachelard, with the indemnity expiring upon loan maturity on August 26, 2026.
• On April 22, 2020, EDAP Technomed Co. Ltd (Japan) contracted another loan for 50,000,000 JPY, requiring a personal guarantee from its representative director, Mr. Jean-Franois Bachelard. EDAP TMS S.A. counter-guaranteed this loan and agreed to indemnify Mr. Bachelard, with the indemnity expiring upon loan maturity on April 2, 2025.

Stakeholder Impact

• Shareholders: The proposed resolutions, particularly those concerning capital increases and executive compensation, will directly impact shareholder rights and potential dilution. The company's financial performance and going concern status are critical for shareholder value.
• Employees: The company's commitment to fostering a culture of inclusion, professional development, and employee wellbeing is noted. The proposed free share grants aim to align employee interests with shareholders.
• Creditors: The company's financial health and ability to meet its debt obligations, including those related to the EIB loan and Banque Palatine credit agreement, are crucial for creditors. The recent waivers from Banque Palatine and EIB mitigate immediate default risks.
• Suppliers: The company's reliance on single-source suppliers for certain components poses a risk that could impact operations and, consequently, supplier relationships if production is significantly disrupted.

Next Steps

• Shareholders are invited to attend the Ordinary and Extraordinary General Meeting of Shareholders on June 26, 2026.
• Shareholders are requested to vote on the 32 proposed resolutions.
• The Board of Directors will report to the next ordinary shareholders meeting on the use made of any delegated authorities for capital increases.

Key Dates

Recommendation

While the company's strategic focus on HIFU technology and expansion into new indications is positive, the significant net losses, declining cash position, and ongoing concerns about its ability to continue as a going concern present substantial risks. The upcoming shareholder meeting addresses critical governance and financial matters, but the immediate financial performance and liquidity challenges warrant a cautious 'hold' recommendation until a clearer path to profitability and sustainable operations is demonstrated.

Keywords

EDAP TMS SA, Proxy Statement, Annual General Meeting, Shareholder Meeting, Director Elections, Executive Compensation, Financial Statements, Capital Increase, Bylaw Amendments, HIFU Technology, Prostate Cancer Treatment, Medical Devices